Trials / Completed
CompletedNCT01335035
Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study has been designed to establish the efficacy and safety of deferasirox in patients with iron overload from 6 to 18 months after allogeneic hematopoietic stem cell transplant (HSCT). The purpose of this study is to assess the mean change in serum ferritin after 52 weeks of treatment with deferasirox, in patients with iron overload (defined with serum ferritin levels ≥ 1000 ng/ml and receiving \> 20 RBC concentrates) after allogeneic HSCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | deferasirox |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2011-05-01
- First posted
- 2011-04-13
- Last updated
- 2012-05-01
Locations
9 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01335035. Inclusion in this directory is not an endorsement.